1. [Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders].
- Author
-
Kurkin DV, Morkovin EI, Bakulin DA, Gorbunova YV, Ivanova OV, Pavlova EV, Zvereva VI, Dzhavakhyan MA, Krysanov IS, Kolosov YA, Zaborovsky AV, Strygin AV, Petrov VI, Beliy PA, Zaslavskaya KY, Maltsev DV, and Skripka MO
- Subjects
- Humans, Antidepressive Agents therapeutic use, Animals, Receptors, N-Methyl-D-Aspartate metabolism, Receptors, AMPA metabolism, Depressive Disorder drug therapy, Depressive Disorder metabolism
- Abstract
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.
- Published
- 2024
- Full Text
- View/download PDF